Shots:

• The P-III IMvigor130 study involves assessing of Tecentriq + platinum-based CT vs platinum based-CT as monothx. in 1213 patients with metastatic urothelial carcinoma (mUC) prior not treated with systemic therapy
• The P-III IMvigor130 study resulted in meeting its 1EPs of PFS with the reduction in the risk of disease worsening or death- improved OS and no new safety signals were observed
• Tecentriq (atezolizumab) is a mAb targeting PD-L1- blocking its interaction with PD-1 and B7.1 receptors- being evaluated in four ongoing P-III studies for early and advanced bladder cancer and is an approved therapy for mUC- NSCLC- PD-L1+ triple-negative breast cancer

Click here to­ read full press release/ article

 Ref: Roche | Image: Roche